MedTrace Logo

Feasibility of IPL Combined With RF for Treatment of DED Due to MGD

NCT05487547 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-01-18

No results posted yet for this study

Summary

The purpose of this single-arm pilot study is to evaluate the feasibility and safety of combination therapy of intense pulsed light (IPL) and (Radiofrequency) RF for treatment of Dry eye disease (DED) due to Meibomian gland dysfunction (MGD).

Conditions

Interventions

DEVICE

IPL_RF_MGX

intense pulsed light followed by Radiofrequency followed by meibomian gland expression

Sponsors & Collaborators

  • Lumenis Be Ltd.

    lead INDUSTRY

Principal Investigators

  • James Chelnis, MD · Manhattan Face and Eye

  • Chantel Garcia, OD · Carolina Eye Doctors

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2022-12-28
Completion
2022-12-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05487547 on ClinicalTrials.gov